Allarity Therapeutics, Inc. (ALLR)Healthcare | Biotechnology | Boston, United States | NasdaqCM
1.23 USD
-0.01
(-0.806%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.21 -0.02 (-0.020%) ⇩ (April 17, 2026, 7:59 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:02 a.m. EDT
Despite severe fundamental risks and a near-term bearish statistical forecast, ALLR represents a high-conviction long-term speculative buy driven by a potential biotech catalyst (FDA Fast Track) and a stark discount to analyst expectations, though investors should ignore the short-term technical volatility and trading volume phenomena. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.120839 |
| MSTL | 0.139555 |
| AutoTheta | 0.140557 |
| AutoETS | 0.140641 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.321 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.245 |
| Revenue per Share | 0.022 |
| Market Cap | 19,457,346 |
| Forward P/E | -1.27 |
| Beta | 0.01 |
| Previous Name | Oncology Venture A/S |
| Website | https://www.allarity.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19417477 |
| Address1 | 24 School Street |
| Address2 | 2nd Floor |
| All Time High | 15,288,000.0 |
| All Time Low | 0.614 |
| Ask | 1.24 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 126,080 |
| Average Daily Volume3 Month | 168,850 |
| Average Volume | 168,850 |
| Average Volume10Days | 126,080 |
| Beta | 0.007 |
| Bid | 1.21 |
| Bid Size | 1 |
| Book Value | 0.516 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.23 |
| Current Ratio | 2.127 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.23 |
| Day Low | 1.2 |
| Debt To Equity | 14.245 |
| Display Name | Allarity Therapeutics |
| Ebitda | -12,596,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.483 |
| Enterprise To Revenue | 19.023 |
| Enterprise Value | 6,087,345 |
| Eps Current Year | -0.96 |
| Eps Forward | -0.97 |
| Eps Trailing Twelve Months | -0.78 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.08262 |
| Fifty Day Average Change | 0.14738 |
| Fifty Day Average Change Percent | 0.1361327 |
| Fifty Two Week Change Percent | 19.417477 |
| Fifty Two Week High | 2.35 |
| Fifty Two Week High Change | -1.1199999 |
| Fifty Two Week High Change Percent | -0.47659573 |
| Fifty Two Week Low | 0.769 |
| Fifty Two Week Low Change | 0.46100003 |
| Fifty Two Week Low Change Percent | 0.59947985 |
| Fifty Two Week Range | 0.769 - 2.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,640,097,000,000 |
| Float Shares | 15,794,144 |
| Forward Eps | -0.97 |
| Forward P E | -1.2680413 |
| Free Cashflow | -10,213,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 320,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03508 |
| Held Percent Institutions | 0.08168 |
| Implied Shares Outstanding | 15,818,980 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-21 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,726,012,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts. |
| Long Name | Allarity Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 19,457,346 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_225998297 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -11,231,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 19,457,345 |
| Number Of Analyst Opinions | 1 |
| Open | 1.21 |
| Operating Cashflow | -14,820,000 |
| Operating Margins | -9.11875 |
| Payout Ratio | 0.0 |
| Phone | 401 426 4664 |
| Post Market Change | -0.01999998 |
| Post Market Change Percent | -1.6260147 |
| Post Market Price | 1.21 |
| Post Market Time | 1,776,470,359 |
| Prev Name | Oncology Venture A/S |
| Previous Close | 1.24 |
| Price Eps Current Year | -1.28125 |
| Price Hint | 4 |
| Price To Book | 2.383721 |
| Price To Sales Trailing12 Months | 60.804207 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.858 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.806451 |
| Regular Market Day High | 1.23 |
| Regular Market Day Low | 1.2 |
| Regular Market Day Range | 1.2 - 1.23 |
| Regular Market Open | 1.21 |
| Regular Market Previous Close | 1.24 |
| Regular Market Price | 1.23 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 55,926 |
| Return On Assets | -0.38516 |
| Return On Equity | -1.03803 |
| Revenue Per Share | 0.022 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,818,980 |
| Shares Percent Shares Out | 0.0224 |
| Shares Short | 353,879 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 227,623 |
| Short Name | Allarity Therapeutics, Inc. |
| Short Percent Of Float | 0.0224 |
| Short Ratio | 1.98 |
| Source Interval | 15 |
| State | MA |
| Symbol | ALLR |
| Target High Price | 9.75 |
| Target Low Price | 9.75 |
| Target Mean Price | 9.75 |
| Target Median Price | 9.75 |
| Total Cash | 14,770,000 |
| Total Cash Per Share | 0.934 |
| Total Debt | 1,400,000 |
| Total Revenue | 320,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.20391 |
| Two Hundred Day Average Change | 0.026090026 |
| Two Hundred Day Average Change Percent | 0.021671077 |
| Type Disp | Equity |
| Volume | 55,926 |
| Website | https://www.allarity.com |
| Zip | 2,108 |